MAJIC-PV Trial Outcomes: Guiding Treatment Decisions for Hydroxyurea-Resistant Polycythemia Vera
Panelists discuss how the MAJIC-PV trial provides critical evidence that ruxolitinib offers more than symptomatic relief in polycythemia vera, demonstrating approximately 40% reduction in thromboembolic events and improved event-free survival while …